A presentation with Dr. Doug Kerr, Chief Medical Officer at Dyne Therapeutics. Dr. Kerr shares topline results from the DELIVER clinical trial, along with new long-term data showing sustained benefits out to 24 months.
DELIVER is Dyne’s global, randomized, placebo-controlled, double-blind, Phase 1/2 trial that evaluated the safety, tolerability and efficacy of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy who have mutations in the DMD gene that are amenable to exon 51 skipping.
Recorded: Friday, December 12, 2025
* Zeleciment rostudirsen is investigational or otherwise in development and has not been approved as safe or effective by the US FDA, EMA, or any other regulatory authority.
The post Dyne Webinar: Positive Topline Results from DELIVER trial in Exon 51 DMD appeared first on CureDuchenne.